BGB-53038

Other Medications

Experimental

Not available 1 Clinical Trials

Description

BGB-53038 is an experimental drug being studied by BeiGene. It is currently in Phase 1 clinical trials for colorectal cancer (CRC). This trial is specifically looking at patients whose tumors have KRAS mutations or amplification. KRAS mutations are common in CRC and can make the cancer resistant to certain treatments. BGB-53038 is being investigated to see if it can safely target KRAS and potentially slow or stop the growth of these types of CRC. The trial is designed to determine the right dose and assess the drug's safety and effectiveness, both alone and in combination with other treatments like cetuximab (a targeted therapy commonly used in CRC) and tislelizumab (an immunotherapy). As it's in Phase 1, the primary goal is safety, but researchers will also look for early signs that the drug is working.

Mechanism of Action

BGB-53038 is being developed as a 'Pan-KRAS inhibitor'. This means it is designed to target the KRAS protein, which is involved in cell growth and division. KRAS mutations can lead to uncontrolled cell growth, a hallmark of cancer. By inhibiting KRAS, the drug aims to block the signals that tell cancer cells to grow and divide. The specific way BGB-53038 interacts with the KRAS protein is being studied in clinical trials.

Side Effects

Because BGB-53038 is an experimental drug in Phase 1 trials Its side effects are still being carefully evaluated. The main goal of Phase 1 trials is to determine the safety and tolerability of the drug. Information about specific side effects will become clearer as more patients are treated in the trials. Common side effects in early cancer drug trials can vary widely depending on the drug's mechanism and dose But can include fatigue Nausea Diarrhea And changes in blood counts. The trial will closely monitor participants for any adverse events.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06585488 Phase 1

Recruiting

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

United States, Australia, China, New Zealand, South Korea

Quick Info

Category	Other Medications
EMA Status	Experimental
Spain Access	Not available
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.